United States· US:70710-1478_62ff03a3-fb25-41d8-9c6c-d1ad61ea3d31
Fomepizole
A fomepizole product containing fomepizole, registered in United States by Zydus Pharmaceuticals USA Inc.. The same ATC class is registered in 14 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Fomepizole is registered in 14 of 19 countries.
Countries holding a registration under ATC V03AB34 (fomepizole), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 7 of them publish a price we can compare per daily dose
Fomepizole · ATC V03AB34
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Sweden
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- FOMEPIZOLE
- Manufacturer
- Zydus Pharmaceuticals USA Inc.
- Country
- United States (US)
- ATC code
- V03AB34
- ATC class
- Fomepizole
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1170710147811 VIAL in 1 CARTON (70710-1478-1) / 1.5 mL in 1 VIAL
- ndc1170710-1478-1
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
4 interactions on record for fomepizole.
Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Fomepizole · interactions on record
4 records
- 4 severe
Most severe, free to view
- EthanolB05XX04severe
- EthanolV03AB16severe
- EthanolV03AZ01severe
- EthanolV07AB03severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Fomepizole in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomAntizol 1.5g/1.5ml solution for infusion vialsImported (United States)
- CanadaANTIZOLENDO OPERATIONS LTD.
- FranceFOMEPIZOLE AP-HP 5 mg/mL, solution à diluer pour perfusionASSISTANCE PUBLIQUE - HOPITAUX DE PARIS - AP-HP
- IcelandFOMEPIZOLE SERBSERB S.A.
- NetherlandsFomepizole SERB 5 mg/ml, concentraat voor oplossing voor infusieSERB S.A.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- France · Fomepizole Ap-Hp
- United Kingdom (Northern Ireland) · Fomepizole Waymade
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cf7d10b7-122c-4b7d-a25b-e5c73d19601d GET /v1/drugs/cf7d10b7-122c-4b7d-a25b-e5c73d19601d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": "1",
"substance": "FOMEPIZOLE",
"productndc": "70710-1478",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"strength_unit": "g/mL",
"application_number": "ANDA078537",
"marketing_category": "ANDA"
}See everything about fomepizole.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.